RCKT
Rocket Pharmaceuticals, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Sell
-44/100
Last price
2.48
▼ 0.13 (4.94%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.52
Prev close
2.61
Day high
2.62
Day low
2.46
Volume
1.79M
Market cap
$272.24M
P/E (TTM)
—
52W range
2.46 – 5.45
Day trading desk
Gap from prior close
-3.53%
Prior close 2.61
VWAP
2.49
-0.39% from price
Relative volume
1.94×
Unusually busy
Session range
8.13%
2.46 – 2.66
Position in range
10%
Near session low
ATR (14D)
0.19
7.83% of price
Prior day high
2.63
PDH
Prior day low
2.50
PDL
Bid / ask spread
—
Quote not published
Session volume
3.29M
Avg 1.69M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.25%
-6.2%
1M
-35.75%
-36.9%
3M
-41.51%
-46.0%
6M
-28.74%
-46.9%
YTD
-29.34%
-43.6%
1Y
-21.27%
-37.7%
3Y
-87.90%
-170.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on RCKT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+82.23K
Net buying
Buy transactions
8
291.94K shares
Sell transactions
15
209.71K shares
Net transactions
+23
Buys less sells
Sell : buy shares
0.7 : 1
Mixed
Insider-held shares
3.49M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 11, 26 | WILSON MARTIN General Counsel |
SELL | 75.36K | $256.46K | Direct |
| Aug 18, 26 | WILSON MARTIN General Counsel |
SELL | 631 | $2.13K | Direct |
| Aug 18, 26 | SHAH GAURAV D Chief Executive Officer |
SELL | 2.29K | $7.75K | Direct |
| Aug 13, 26 | WILSON MARTIN General Counsel |
SELL | 3.49K | $11.81K | Direct |
| Aug 13, 26 | SHAH GAURAV D Chief Executive Officer |
SELL | 2.84K | $9.59K | Direct |
| Aug 11, 26 | CHAUDHURI SARBANI Officer |
SELL | 4.70K | $16.45K | Direct |
| Aug 11, 26 | STEVENS CHRISTOPHER JAMES Chief Operating Officer |
SELL | 36.66K | $128.27K | Direct |
| Aug 3, 26 | STEVENS CHRISTOPHER JAMES Chief Operating Officer |
STOCK | 73.31K | $0 | Direct |
| Jun 18, 26 | FONG PETER PH.D. Director |
STOCK | 22.86K | $0 | Direct |
| Jun 18, 26 | SOUTHWELL DAVID P Director |
STOCK | 22.86K | $0 | Direct |
| Jun 18, 26 | BOESS CARSTEN Director |
STOCK | 22.86K | $0 | Direct |
| Jun 18, 26 | DOLSTEN MIKAEL Director |
STOCK | 22.86K | $0 | Direct |
| Jun 18, 26 | WONG RODERICK Director and Beneficial Owner of more than 10% of a Class of Security |
STOCK | 27.83K | $0 | Direct |
| Jun 18, 26 | MALIK FADY IBRAHAM Director |
STOCK | 22.86K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHAUDHURI SARBANI |
Officer | 262.81K | Sale |
MAKKER GOTHAM |
Director | — | Stock Award(Grant) |
PATEL KINNARI |
Chief Operating Officer | 573.63K | Sale |
RIZVI SYED ALI-AAMIR M.D. |
Officer | 407.87K | Stock Award(Grant) |
RTW INVESTMENTS, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
SCHWARTZ JONATHAN DAVID |
Officer | 299.06K | Sale |
SHAH GAURAV D |
Chief Executive Officer | 1.46M | Sale |
STEVENS CHRISTOPHER JAMES |
Chief Operating Officer | 505.78K | Sale |
WILSON MARTIN |
General Counsel | 598.49K | Sale |
WONG RODERICK |
Director and Beneficial Owner of more than 10% of a Class of Security | 18.26M | Stock Award(Grant) |
Fundamentals
Market cap$272.24M
Enterprise value$13.29M
Revenue (TTM)—
Gross profit—
EBITDA$-182.18M
Net income$-17.25M
EPS (TTM)$-0.16
Free cash flow$86.14M
Total cash$283.75M
Total debt$24.80M
Book value / share$3.37
Shares outstanding109.77M
Float87.62M
Short % of float16.58%
Dividend yield0.00%
Beta (5Y)0.50
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.90
PEG ratio—
Price / sales—
Price / book0.74
EV / revenue—
EV / EBITDA-0.07
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-4.77%
Return on assets-28.42%
Debt / equity6.72
Current ratio9.25
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $142.01M | $171.24M | $186.34M | $165.57M | -17.1% |
| Selling, general & admin | $86.50M | $101.96M | $73.32M | $58.77M | -15.2% |
| Total operating expense | $228.52M | $273.20M | $259.66M | $223.84M | -16.4% |
| Operating income | -$228.52M | -$273.20M | -$259.66M | -$223.84M | +16.4% |
| Net interest income | $8.62M | $14.46M | $14.06M | $1.98M | -40.4% |
| Pre-tax income | -$223.12M | -$258.75M | -$245.59M | -$221.86M | +13.8% |
| Net income | -$223.12M | -$258.75M | -$245.59M | -$221.86M | +13.8% |
| Net income to common | -$223.12M | -$258.75M | -$245.59M | -$221.86M | +13.8% |
| Basic EPS | -2.01 | -2.73 | -2.92 | -3.26 | +26.4% |
| Diluted EPS | -2.01 | -2.73 | -2.92 | -3.26 | +26.4% |
| EBIT | -$221.23M | -$256.86M | -$243.72M | -$219.95M | +13.9% |
| EBITDA | -$210.21M | -$247.49M | -$236.62M | -$213.69M | +15.1% |
| Basic shares | 111.12M | 94.81M | 84.01M | 68.15M | +17.2% |
| Diluted shares | 111.12M | 94.81M | 84.01M | 68.15M | +17.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $77.56M | $163.63M | $55.90M | $140.52M | -52.6% |
| Cash & short-term investments | $188.93M | $372.34M | $373.18M | $356.39M | -49.3% |
| Total current assets | $192.73M | $378.18M | $378.22M | $364.06M | -49.0% |
| Property, plant & equipment | $71.59M | $83.32M | $87.59M | $77.64M | -14.1% |
| Goodwill & intangibles | $64.30M | $64.30M | $64.30M | $64.88M | 0.0% |
| Total assets | $330.45M | $527.70M | $566.34M | $551.81M | -37.4% |
| Total current liabilities | $30.21M | $40.68M | $48.51M | $39.17M | -25.8% |
| Total debt | $24.88M | $25.50M | $25.04M | $22.87M | -2.4% |
| Total liabilities | $53.23M | $64.47M | $73.77M | $62.12M | -17.4% |
| Retained earnings | -$1.44B | -$1.22B | -$959.37M | -$713.77M | -18.3% |
| Shareholder equity | $277.22M | $463.23M | $492.57M | $489.69M | -40.2% |
| Working capital | $162.53M | $337.50M | $329.72M | $324.89M | -51.8% |
| Net tangible assets | $212.92M | $398.93M | $428.27M | $424.81M | -46.6% |
| Shares issued | 108.32M | 106.45M | 90.28M | 79.12M | +1.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$223.12M | -$258.75M | -$245.59M | -$221.86M | +13.8% |
| Depreciation & amortisation | $11.03M | $9.38M | $7.10M | $6.27M | +17.6% |
| Stock-based compensation | $37.06M | $43.92M | $39.41M | $31.01M | -15.6% |
| Change in working capital | -$8.26M | $5.67M | $13.82M | $6.08M | -245.7% |
| Operating cash flow | -$190.01M | -$209.72M | -$194.92M | -$178.14M | +9.4% |
| Capital expenditure | -$440.00K | -$5.86M | -$16.47M | -$8.62M | +92.5% |
| Investing cash flow | $103.77M | $131.71M | -$98.07M | -$69.33M | -21.2% |
| Share buybacks | -$67.00K | $0 | $0 | -$47.00K | — |
| Financing cash flow | $148.00K | $185.74M | $208.40M | $155.29M | -99.9% |
| Free cash flow | -$190.45M | -$215.59M | -$211.39M | -$186.76M | +11.7% |
| End cash position | $78.90M | $165.00M | $57.28M | $141.86M | -52.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $29.50M | $31.45M | $29.35M | $34.07M | $42.66M | -6.2% |
| Selling, general & admin | $17.43M | $17.06M | $14.68M | $18.35M | $25.02M | +2.2% |
| Total operating expense | $46.92M | $48.51M | $44.03M | $52.42M | $67.68M | -3.3% |
| Operating income | -$46.92M | -$48.51M | -$44.03M | -$52.42M | -$67.68M | +3.3% |
| Net interest income | $567.00K | $917.00K | $1.43M | $1.92M | $2.23M | -38.2% |
| Pre-tax income | $131.84M | -$47.59M | -$42.54M | -$50.33M | -$68.92M | +377.0% |
| Tax provision | $8.62M | — | — | — | $0 | — |
| Net income | $123.21M | -$47.59M | -$42.54M | -$50.33M | -$68.92M | +358.9% |
| Net income to common | $123.21M | -$47.59M | -$42.54M | -$50.33M | -$68.92M | +358.9% |
| Basic EPS | 1.09 | -0.42 | -0.38 | -0.45 | -0.62 | +359.5% |
| Diluted EPS | 1.08 | -0.42 | -0.38 | -0.45 | -0.62 | +357.1% |
| EBIT | $132.31M | -$47.12M | -$42.06M | -$49.86M | -$68.45M | +380.8% |
| EBITDA | $134.41M | -$44.98M | -$39.85M | -$46.62M | -$65.87M | +398.9% |
| Basic shares | 112.84M | 112.13M | 111.79M | 111.57M | 111.02M | +0.6% |
| Diluted shares | 114.51M | 112.13M | 111.79M | 111.57M | 111.02M | +2.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $224.51M | $49.61M | $77.56M | $75.95M | $32.82M | +352.5% |
| Cash & short-term investments | $283.75M | $144.38M | $188.93M | $222.76M | $271.49M | +96.5% |
| Total current assets | $289.55M | $149.83M | $192.73M | $227.68M | $277.15M | +93.3% |
| Property, plant & equipment | $67.42M | $69.45M | $71.59M | $74.17M | $77.64M | -2.9% |
| Goodwill & intangibles | $64.30M | $64.30M | $64.30M | $64.30M | $64.30M | 0.0% |
| Total assets | $423.10M | $285.41M | $330.45M | $368.03M | $420.98M | +48.2% |
| Total current liabilities | $31.32M | $24.47M | $30.21M | $31.17M | $43.40M | +28.0% |
| Total debt | $24.80M | $24.76M | $24.88M | $25.05M | $25.20M | +0.1% |
| Total liabilities | $54.27M | $47.37M | $53.23M | $54.36M | $66.77M | +14.6% |
| Retained earnings | -$1.37B | -$1.49B | -$1.44B | -$1.40B | -$1.35B | +8.3% |
| Shareholder equity | $368.83M | $238.04M | $277.22M | $313.67M | $354.21M | +54.9% |
| Working capital | $258.23M | $125.36M | $162.53M | $196.51M | $233.76M | +106.0% |
| Net tangible assets | $304.53M | $173.74M | $212.92M | $249.37M | $289.91M | +75.3% |
| Shares issued | 109.54M | 109.12M | 108.32M | 108.21M | 107.88M | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $123.21M | -$47.59M | -$42.54M | -$50.33M | -$68.92M | — | +358.9% |
| Depreciation & amortisation | $2.10M | $2.15M | $2.22M | $3.24M | $2.58M | — | -2.0% |
| Stock-based compensation | $7.42M | $8.49M | $6.11M | $9.76M | $10.86M | — | -12.6% |
| Change in working capital | $6.48M | -$7.42M | $195.00K | -$11.49M | $8.73M | — | +187.4% |
| Operating cash flow | -$39.61M | -$45.39M | -$34.84M | -$50.42M | -$48.96M | — | +12.7% |
| Capital expenditure | -$8.00K | -$93.00K | -$80.00K | — | -$50.00K | -$364.00K | +91.4% |
| Investing cash flow | $214.36M | $17.45M | $36.42M | $93.62M | $31.76M | — | +1,128.6% |
| Share buybacks | — | — | $0 | — | — | — | — |
| Financing cash flow | $150.00K | -$1.00K | $0 | -$67.00K | $215.00K | — | +15,100.0% |
| Free cash flow | -$39.62M | -$45.49M | -$34.92M | -$50.37M | -$49.01M | — | +12.9% |
| End cash position | $225.85M | $50.95M | $78.90M | $77.31M | $34.18M | — | +343.3% |
Options analytics
Put / call volume
0.39
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.50
+0.8% from spot
ATM implied vol
3.1%
Nearest strike to spot
Skew (10% OTM)
-3.1%
Calls bid over puts
Call volume
264
Contracts, this expiry
Put volume
104
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
2.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.27 | -0.38 | -244.2% |
| Mar 2026 | -0.43 | -0.42 | +3.1% |
| Dec 2025 | -0.42 | -0.38 | +10.4% |
| Sep 2025 | -0.52 | -0.45 | +12.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.41 | 5 | $181.82K | 0.0% |
| Next quarter | -0.41 | 5 | $624.64K | 0.0% |
| Current year | -0.11 | 4 | $1.11M | 0.0% |
| Next year | -1.30 | 5 | $11.25M | +915.6% |
Analyst targets & ownership
Mean target$8.85
High target$15.00
Low target$3.00
Implied upside256.88%
Analyst count12
ConsensusBUY
Strong buy / Buy1 / 6
Hold5
Sell / Strong sell1 / 1
Held by insiders3.18%
Held by institutions91.79%
Institutions holding248
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.64
-5.93% from price
SMA 20
3.03
-18.21% from price
SMA 50
3.33
-25.57% from price
SMA 100
3.29
-24.68% from price
SMA 200
3.56
-30.29% from price
EMA 12
2.76
-10.08% from price
EMA 26
3.03
-18.12% from price
EMA 50
3.21
-22.79% from price
RSI (14)
27.3
Oversold
MACD (12,26,9)
-0.27
Hist -0.05
ATR (14)
0.19
7.83% of price
Realised vol 30D
63.1%
Annualised
Bollinger upper
3.86
20, 2σ
Bollinger lower
2.21
20, 2σ
50 / 200 cross
Death
3.33 vs 3.56
Trend bias
Below 200
-30.29%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.79
More volatile than market
Correlation to SPY
0.32
Loosely linked
Realised vol 30D
63.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-53.2%
Peak to trough
Max drawdown 5Y
-93.5%
Peak to trough
ATR 14
0.19
7.83% of price
Beta (reported)
0.50
5Y monthly, from filing
Short interest
Shares short
14.85M
Prior 14.39M
Change vs prior
+3.2%
Shorts adding
% of float
16.58%
Elevated
% of shares out
13.53%
Against total outstanding
Days to cover
10.3
Crowded exit
Float
87.62M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 16, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Sep 16, 26 | Needham | UPGRADE | Hold | Buy |
| Sep 15, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Sep 1, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Aug 11, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| May 11, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Mar 30, 26 | B of A Securities | MAINTAINED | Buy | Buy |
| Mar 27, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Mar 2, 26 | Goldman Sachs | MAINTAINED | Sell | Sell |
| Feb 27, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Nov 18, 25 | B of A Securities | MAINTAINED | Buy | Buy |
| Nov 18, 25 | JP Morgan | DOWNGRADE | Overweight | Underweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay dateJan 5, 2018
Last split1:4
Split dateJan 5, 2018
SEC filings
Notification filed by national security exchange to report the removal from listing and registration of matured
25-NSE · 2026-09-02
Corporate Changes & Voting Matters
8-K · 2026-08-27
Corporate Changes & Voting Matters
8-K · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-08-03
Offering Registrations
S-8 · 2026-07-14
Corporate Changes & Voting Matters
8-K · 2026-06-30
Corporate Changes & Voting Matters
8-K · 2026-06-12
Tender Offer/Acquisition Reports
SC TO-I/A · 2026-05-28
Headlines
Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset
MarketBeat · 3h ago
Rocket Secures Credit Facility From Hercules Capital
MT Newswires · 9h ago
Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
Business Wire · 9h ago
Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?
Insider Monkey · 14d ago
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
BioPharma Dive · 19d ago
Rocket Pharmaceuticals Shares Rise After Needham Upgrade
MT Newswires · 20d ago
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
Zacks · 21d ago
Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls
The Fly · 21d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.